Clinical Trial

NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

Study acronym: NACAM
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2025 (before its estimated April 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-02-10; most recent amendment 2025-03-10.
Status change: Not Yet Recruiting → Recruiting 2021-09-24
Trial Details
NCT Number NCT04750616
Lead Sponsor Kaiser Permanente
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Beth Israel Deaconess Medical Center, Cedars-Sinai Medical Center
Conditions Ischemia Reperfusion Injury, Myocardial Injury, Acute Kidney Injury
Enrollment 304 participants
Start Date 2021-09-13
Primary Completion 2025-04-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-12